Fibrates for Primary Biliary Cholangitis: What's All the Hype?

Area of Science:

• Hepatology
• Gastroenterology
• Clinical Pharmacology

Background:

• Primary biliary cholangitis (PBC) is a chronic liver disease.
• Ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC.
• A significant subset of patients exhibit an inadequate biochemical response to UDCA, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To review the current landscape of second-line and adjuvant therapies for primary biliary cholangitis.
• To evaluate the efficacy and safety of emerging treatment options for UDCA-unresponsive PBC patients.
• To discuss the role of obeticholic acid and fibrates in managing advanced or refractory PBC.

Main Methods:

• Literature review of clinical trials and observational studies.
• Analysis of treatment guidelines and expert opinions.
• Synthesis of evidence on biochemical response and clinical outcomes.

Main Results:

• Obeticholic acid (OCA) has received conditional approval as a second-line therapy for PBC.
• Growing evidence supports the use of fibrates as an effective off-label adjuvant therapy for PBC.
• Both OCA and fibrates demonstrate potential in improving biochemical markers in non-responders to UDCA.

Conclusions:

• For patients with primary biliary cholangitis who do not respond to ursodeoxycholic acid, second-line and adjuvant therapies are crucial.
• Obeticholic acid and fibrates represent promising therapeutic options for managing UDCA-resistant PBC.
• Further research is needed to establish the long-term efficacy and optimal use of these agents in PBC management.